# NALIRI-XELOX+AK104 for First-line Treatment of Advanced PDAC

> **NCT06405490** · PHASE2 · RECRUITING · sponsor: **Cancer Institute and Hospital, Chinese Academy of Medical Sciences** · enrollment: 30 (estimated)

## Conditions studied

- Nanoliposomal Irinotecan
- Cadonilimab
- Oxaliplatin
- Capecitabine
- First-Line
- Advanced Cancer
- Pancreatic Adenocarcinoma
- Drug Use

## Interventions

- **DRUG:** Nanoliposomal Irinotecan+Oxaliplatin +Capecitabine+Cadonilimab

## Key facts

- **NCT ID:** NCT06405490
- **Lead sponsor:** Cancer Institute and Hospital, Chinese Academy of Medical Sciences
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-04-17
- **Primary completion:** 2026-08-30
- **Final completion:** 2026-12-30
- **Target enrollment:** 30 (ESTIMATED)
- **Last updated:** 2024-12-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06405490

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06405490, "NALIRI-XELOX+AK104 for First-line Treatment of Advanced PDAC". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT06405490. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*